Publications & Posters

Check out the latest posters and publications.

Filter

October 26, 2022 | From Theseus Pharmaceuticals

Preclinical characterization of THE-349, a CNS-active, mutant-selective fourth-generation EGFR inhibitor with potent activity against single, double, and triple mutant EGFR variants including T790M and C797S

Sen Zhang, Wei-Sheng Huang, Sara Nadworny, Emily Ye, Narayana Narasimhan, Charles J. Eyermann, David C. Dalgarno, Victor M. Rivera, William C. Shakespeare EORTC-NCI-AACR (ENA) Symposium

April 8, 2022 | From Theseus Pharmaceuticals

Discovery of potent and selective next-generation EGFR inhibitors with activity against single, double, and triple mutant EGFR variants including T790M and C797S

Wei-Sheng Huang, Sara Nadworny, Sen Zhang, Narayana Narasimhan, Charles J. Eyermann, David C. Dalgarno, Victor M. Rivera, William C. Shakespeare American Association for Cancer Research (AACR)

February 25, 2022 | From External Experts

New treatment strategies for advanced-stage gastrointestinal stromal tumours

Lillian R. Klug, Homma M. Khosroyani, Jason D. Kent and Michael C. Heinrich Nature Reviews | Clinical Oncology

April 15, 2021 | From External Experts

Overcoming therapy resistance in EGFR-mutant lung cancer

Antonio Passaro, Pasi A. Jänne, Tony Mok, Solange Peters Nature Cancer

April 10, 2021 | From Theseus Pharmaceuticals

Preclinical characterization of THE-630, a next-generation inhibitor for KIT-mutant gastrointestinal stromal tumors (GIST)

Victor M. Rivera, Wei-Sheng Huang, Mengrou Lu, Justin R. Pritchard, David Dalgarno, William C. Shakespeare American Association for Cancer Research (AACR)

We are targeting cancers where current therapies are limited by the burden of treatment resistance.

LEARN ABOUT OUR DISEASE FOCUS